化疗放疗（CRT）是一种常规治疗在局部癌症中使用，特别是在其处于局部晚期时。研究表明，CRT在临床前模型和人类中引起了多种免疫效应，诱导了强烈的抗肿瘤反应。在本次综述中，我们描述了CRT疗效所涉及的各种免疫效应。实际上，像免疫细胞死亡，抗原呈递细胞的激活和成熟，以及适应性抗肿瘤免疫反应的激活都归因于CRT。就像其他疗法中经常描述的那样，由Treg和髓样细胞群体特别介导的各种免疫抑制机制可能会降低CRT的疗效。因此，我们讨论了将CRT与其他疗法联合使用，以增强CRT诱导的抗肿瘤效应的相关性。版权所有©2023 Elsevier Inc.。保留所有权利。

Chemoradiation (CRT) is a conventional therapy used in local cancers, especially when they are locally advanced. Studies have shown that CRT induces strong anti-tumor responses involving several immune effects in pre-clinical models and humans. In this review, we have described the various immune effects involved in CRT efficacy. Indeed, effects such as immunological cell death, activation and maturation of antigen-presenting cells, and activation of an adaptive anti-tumor immune response are attributed to CRT. As often described in other therapies, various immunosuppressive mechanisms mediated, in particular, by Treg and myeloid populations may reduce the CRT efficacy. We have therefore discussed the relevance of combining CRT with other therapies to potentiate the CRT-induced anti-tumor effects.Copyright © 2023 Elsevier Inc. All rights reserved.